InvestorsHub Logo
Followers 6
Posts 231
Boards Moderated 0
Alias Born 05/19/2015

Re: hessmessinc post# 57290

Sunday, 03/20/2016 11:13:19 PM

Sunday, March 20, 2016 11:13:19 PM

Post# of 467087
If we don't pass the pivotal trial (and that is assuming we even make it to one) , anavexes will have to dilute to afford other p2s for the other applications and this goes in the dirt. There is always risk in biotech. 12,,26, and 52 week data is extremely telling and important for the future.

Fast track or breakthrough will also be a major part of getting to market by 2018. That is nearly only a year away by now and p2/3 isn't even started yet
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News